Ibipinabant

N/A

Report date: 2025/07/11 20:01:15
NME

Base Information

Drug NameIbipinabant
Drug Alias Nameibipinabantum伊匹纳班伊必那班SLV-319BMS-646256
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG